Canadian pharmacologist (1934–2021)
Philip Seeman
Born (1934-02-08 ) 8 February 1934Died 9 January 2021(2021-01-09) (aged 86) Awards Order of Canada
Philip Seeman , OC FRSC (8 February 1934 – 9 January 2021) was a Canadian schizophrenia researcher and neuropharmacologist , known for his research on dopamine receptors.[ 1]
Career
Born in Winnipeg , Manitoba , Seeman was raised in Montreal . He received a Bachelor of Science degree, honours physics & physiology (1955), a Master of Science degree, physiology of transport & secretion (1956), and a Doctor of Medicine (1960) from McGill University . In 1966, he received a Ph.D. in life sciences from Rockefeller University under the supervision of George Emil Palade .[ 2]
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the University of Toronto . In 1970, he was appointed a professor.
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the dopamine D2 receptor , the basis for the dopamine hypothesis of schizophrenia .[ 3] [ 4] His discoveries also helped advance research on other diseases involving dopamine, such as Parkinson's disease and Huntington's disease .[ 2]
In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".[ 5]
In 1985, he was made a Fellow of the Royal Society of Canada .[ 6]
He was married to Dr. Mary V. Seeman .[ 7]
Notes
References
Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives . 22 (1): 62– 78. doi :10.1080/0964704x.2012.678199 . PMID 23323533 . S2CID 12002684 .
Seeman, P. (2011). "All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors" . CNS Neuroscience & Therapeutics . 17 (2): 118– 132. doi :10.1111/j.1755-5949.2010.00162.x . PMC 6493870 . PMID 20560996 .
P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets . 10 (4): 515– 531. doi :10.1517/14728222.10.4.515 . PMID 16848689 . S2CID 30902536 .
Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T.; Boksa, P.; El-Ghundi, M.; O'Dowd, B.F.; George, S.R.; Perreault, M.L.; Mannisto, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis" . Proceedings of the National Academy of Sciences USA . 102 (9): 3513– 3518. Bibcode :2005PNAS..102.3513S . doi :10.1073/pnas.0409766102 . PMC 548961 . PMID 15716360 .
Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975). "Brain receptors for antipsychotic drugs and dopamine: Direct binding assays" . Proceedings of the National Academy of Sciences, USA . 72 (11): 4376– 4380. Bibcode :1975PNAS...72.4376S . doi :10.1073/pnas.72.11.4376 . PMC 388724 . PMID 1060115 .
External links